PubMed Health⌕ Search

Biomedical subjects

K Hatch

Publications and source records attributed to K Hatch.

23 records · Page 2Linked to original sources
PubMed1986

Phase II trials of cisplatin and piperazinedione as single agents in the treatment of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study.

A total of 42 patients with advanced or recurrent carcinoma of the cervix, other than squamous cell carcinoma, were entered onto two phase II studies by the Gynecologic Oncology Group. Of 16 patients registered to receive piperazinedione at a dose of 9 mg/m2 iv every 3 weeks, two were inevaluable for response because of the lack of measurable disease. Of the remaining 14, two (14%) had complete response. Adverse effects were limited to myelosuppression, nausea and vomiting, and nephrotoxicity. Among 26 patients registered to receive cisplatin, three were deemed ineligible and three were inevaluable for the study. Of the remaining 20 patients, one (5%) had complete response and three (15%) had partial response. Primary adverse effects included myelosuppression, frequent nausea and vomiting, and nephrotoxicity. The most common histologic subtypes noted were adenocarcinoma and adenosquamous carcinoma, and responses were noted among patients with each subtype on each drug. Both drugs appear to possess moderate activity against non-squamous carcinoma of the cervix.

Carcinoma↗
PubMed1985

Chemotherapy of cervix cancer with doxorubicin and cisplatin. A phase I pilot study of the Gynecologic Oncology Group.

Twelve women with previously irradiated advanced pelvic cancer were treated with doxorubicin and cisplatin to determine a maximum tolerable dose. Response was not an objective of this phase I study, but one partial response was seen in four cases of cervix cancer with measurable lesions. Hematologic toxicity was frequent and severe at the starting doses (doxorubicin 30 mg/M2 and cisplatin 100 mg/M2 every 3 weeks), but was acceptable when cisplatin was used at 75 mg/M2. Further evaluation of this combination in squamous carcinoma of the cervix is not recommended.

Adult↗
PubMed1984

ICRF-159 (razoxane) in patients with advanced squamous cell carcinoma of the uterine cervix. For the Gynecologic Oncology Group.

Thirty-one patients with advanced squamous cell carcinoma of the cervix were entered onto this phase II study evaluating the efficacy of ICRF-159 (razoxane). Three of these patients were excluded; one had no tumor, one had a second primary, and one received no therapy. ICRF-159 was administered orally at a dose of 2.5 g/m2 weekly until progression, unacceptable toxicity, or death. Adverse effects were primarily hematologic in nature. Twenty-three of the 28 patients exhibited leukopenia which in ten instances was severe (below 2000/mm3). Seven cases had thrombocytopenia (one case below 50,000/mm3). Other toxicity, including fever and anorexia, was mild to moderate. There was tumor response in five (18%) patients (one CR, four PRs) ranging from 1 to 5 months. Fifteen patients with stable disease and eight with progressive disease had a median survival duration of 3.8+ and 3.5+ months, respectively. ICRF-159 showed limited activity in this patient population. However, it might be considered for combination with other low myelosuppressive agents.

Carcinoma, Squamous Cell↗
PubMed1984

Persistence of cerebellar thymidine kinase in staggerer and hypothyroid mutants.

These experiments address the mechanism of action of the persistence of proliferation in the cerebellar external granule layer (EGL) by comparing congenital hypothyroidism due to a recessive mutation in mice to the staggerer mouse mutant. In both cases persistence of the EGL can be demonstrated histologically, with the process more drawn out in staggerer than in hypothyroid. This correlates with higher than normal levels of the enzyme thymidine kinase, a biochemical marker of proliferation, in both mutants. It is hypothesized that the proliferation of EGL cells in both cases is controlled by effects of the mutations on the maturation rate of the Purkinje cells, possibly with other cell types as intermediates.

Aging↗